細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Suppressors Of Cytokine Signaling 3 (SOCS3)
ATOD4; CIS3; Cish3; MGC71791; SOCS-3; SSI-3; SSI3; Cytokine-inducible SH2 protein 3; STAT-induced STAT inhibitor 3
- 編號(hào)SEB684Mu
- 物種Mus musculus (Mouse，小鼠) 相同的名稱(chēng)，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.156-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.059ng/mL.
- 樣本類(lèi)型Tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 2873 ¥ 4104 ¥ 18468 ¥ 34884 ¥ 287280
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB684Mu02 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB684Mu01 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APB684Mu01 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAB684Mu02 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體 | WB; IHC; ICC; IP. |
| PAB684Mu01 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB684Mu71 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| LAB684Mu81 | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| SEB684Mu | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB684Mu | 細(xì)胞因子信號(hào)轉(zhuǎn)導(dǎo)抑制因子3(SOCS3)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| The Journal of Biological Chemistry | Human primary keratinocytes show a restricted ability to up-regulate suppressor of cytokine signaling (SOCS)3 compared to autologous macrophages [Jcb: 280370] |
| The Journal of Biological Chemistry | Human Primary Keratinocytes Show Restricted Ability to Up-regulate Suppressor of Cytokine Signaling (SOCS)3 Protein Compared with Autologous Macrophages [PubMed: PMC3323061] |
| Journal of Reproductive Immunology | What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility? [Pubmed: 24368037] |
| The Journal of Immunology | Alveolar Epithelial Cell–Derived Prostaglandin E2?Serves as a Request Signal for Macrophage Secretion of Suppressor of Cytokine Signaling 3 during Innate Inflammation [Pubmed:27183597] |
| Scientific Reports | The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway [pubmed:28970500] |
| Journal of Immunological Methods | Endogenous peroxidases in sputum interfere with horse-radish peroxidase-based ELISAs. [pubmed:29154772] |
| Turkish?Journal Of?Medical?Sciences | The impact of plasma SOCS3 levels and endometrial leukocytes on unexplained infertility [Pubmed:29914245] |
| Novel trajectories of Bromocriptine antidiabetic action: Leptin-IL-6/JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPARγ/Adiponectin, Nrf2/PARP-1, and GLP-1 [articles:10.3389] | |
| JCI Insight | Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics [Pubmed: 31619584] |
| European Journal of Pharmacology | Olmesartan attenuates type 2 diabetes-associated liver injury: Cross-talk of AGE/RAGE/JNK, STAT3/SCOS3 and RAS signaling pathways [Pubmed: 32067934] |
| FASEB JOURNAL | Resident alveolar macrophage‐derived vesicular SOCS3 dampens allergic airway inflammation [Pubmed: 32030817] |
| molecular immunology | SOCS3-deficient lung epithelial cells uptaking neutrophil-derived SOCS3 worsens lung influenza infection [Pubmed: 32645550] |
| Experimental and Therapeutic Medicine | Changes and clinical significance of serum inflammatory factors in the treatment of pregnancy hypertension syndrome with magnesium sulfate combined with … [Pubmed: 32742411] |
| NEUROCHEMICAL RESEARCH | Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage [33755856] |
| BIOMEDICINE & PHARMACOTHERAPY | Potential contribution of ELISA and LFI Assays to assessment of the oxidative stress condition based on 8-oxodG biomarker [33957564] |
